BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Earnings

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoption Express Scripts national formulary coverage secured as company makes progress toward broad patient access Atrial Fibrillation-RVR Phase 3 registration trial

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

MISTMilestone Pharmaceuticals Inc.2026-03-20 11:55 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

LXRXLexicon Pharmaceuticals2026-05-07 11:30 EST

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

RYTMRhythm Pharmaceuticals2026-05-05 11:00 EST

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

RYTMRhythm Pharmaceuticals2026-08-04 11:01 EST

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

BLTEBelite Bio2026-05-20 10:00 EST

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

SGMTSagimet Biosciences2026-05-12 11:30 EST

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

NAMSNewAmsterdam Pharma2026-05-07 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

MLYSMineralys Therapeutics2026-05-06 20:05 EST

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm. Atrial Fibrillation...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Stock data

Close
1.18 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States